BioCentury
ARTICLE | Company News

BioMarin submits Vimizim MAA

April 25, 2013 12:01 AM UTC

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) submitted an MAA to EMA for Vimizim elosulfase alfa to treat mucopolysaccharidosis IVA (MPS-IVA, Morquio's syndrome). In March, BioMarin submitted a BLA to F...